FGF19 and metabolic dysfunction-associated steatotic liver disease: Reduced fasting plasma levels of FGF19 have been observed in subjects with obesity, T2DM, and MASLD (Alisi et al., 2013; Eren et al., 2012; Mraz et al., 2011).